Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965456 | 0.86 | ALDH1A1 (0.36) | PSMB8LMNAALDH1A1KDM4EMEN1 | |
| SCHEMBL8235296 | 0.77 | TSHR (0.35) | PSMB8CYP1A2CYP2A6TSHRLMNA | |
| SCHEMBL1605524 | 0.76 | KCNN4 (0.41) | PSMB8CYP1A2TSHRLMNAALDH1A1 | |
| SCHEMBL20847883 | 0.75 | ALDH1A1 (0.41) | PSMB8LMNAALDH1A1KDM4EKMT2A | |
| SCHEMBL22542073 | 0.75 | DYRK1A (0.30) | DYRK1AALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29143307 | 0.74 | TSHR (0.39) | CYP1A2CYP2A6TSHRALDH1A1TRPA1 | |
| SCHEMBL21718388 | 0.74 | DYRK1A (0.42) | PSMB8TSHRDYRK1AALDH1A1KDM4E | |
| SCHEMBL2814708 | 0.74 | CYP3A4 (0.41) | TSHRALDH1A1 | |
| SCHEMBL18189333 | 0.74 | SLC22A12 (0.31) | PSMB8 | |
| SCHEMBL3865379 | 0.73 | ACHE (0.32) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360045-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | CORTEVA AGRISCIENCE LLC | 2017-12-21 | — | — | US | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280661-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299136-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-22 | — | — | US | disclosed |
| CN-102648184-B | LXR conditioning agent | EXELIXIS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | PSMB8 2329/4885CYP1A2 2753/4885CYP2A6 2654/4885 |
| US-20170360045-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | PSMB8 3090/4885CYP1A2 906/4885CYP2A6 2392/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | PSMB8 3107/4885CYP1A2 88/4885CYP2A6 45/4885 |
| US-20150299136-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | PSMB8 3107/4885CYP1A2 88/4885CYP2A6 45/4885 |
| US-20160280661-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | PSMB8 3107/4885CYP1A2 88/4885CYP2A6 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.